Medications and Supplements for Hot Flashes
For moderate to severe hot flashes, SSRIs/SNRIs (particularly paroxetine, venlafaxine, or escitalopram) or gabapentin/pregabalin are the recommended first-line pharmacological options when hormone therapy is not desired or contraindicated 1.
Algorithmic Approach to Management
Step 1: Assess Severity and Try Non-Pharmacological Measures First
For mild or less bothersome hot flashes, start with lifestyle modifications 1:
- Lower ambient temperature and dress in layers
- Avoid alcohol and spicy foods
- Reduce stress
- Pursue weight loss if overweight or obese (being overweight is a risk factor for hot flashes)
Step 2: Pharmacological Options for Moderate to Severe Symptoms
When lifestyle measures are insufficient, choose among these evidence-based options:
SSRIs/SNRIs (First-Line)
These reduce hot flash frequency by 25-69% 1:
- Paroxetine mesylate: The only FDA-approved agent in this class for hot flashes
- Venlafaxine: Reduces hot flash scores by approximately 66% and is preferred by most patients over gabapentin 1
- Citalopram and escitalopram: Demonstrated statistically significant efficacy
- Desvenlafaxine: Effective option
Critical caveat: Avoid paroxetine in patients taking tamoxifen, as it markedly interferes with tamoxifen metabolism to its active metabolite endoxifen 1.
Gabapentin (Alternative First-Line)
- Moderately effective with 66% reduction in hot flash scores 1
- Dose range: 300-1200 mg daily (individual requirements vary widely)
- Best for nighttime hot flashes: Use single bedtime dose to leverage sedative effects, which dissipate by morning
- Daytime use may cause intolerable lethargy 1
Pregabalin (Alternative)
- Reduces hot flash scores by 65-71% (vs 50% placebo) at 75-150 mg twice daily 1
- Reasonably well tolerated
Step 3: Understanding Relative Efficacy
Important context: All hot flash treatments have a substantial placebo effect averaging 30% (range 4-57%) 1. The medications above provide additional benefit beyond placebo, with SSRIs/SNRIs and gabapentin reducing hot flashes by approximately 25% or about one additional hot flash per day 2.
While estrogen remains more effective than these nonhormonal options, head-to-head trials show the difference is not as dramatic as commonly assumed 1.
Supplement Evidence
Isoflavones (Soy)
Mixed evidence with hot flash reduction ranging from 9-40% in some trials, though most showed no difference from placebo 3, 4. Overall reduction appears similar to SSRIs/SNRIs when effective 5, but inconsistent results limit recommendation strength.
Vitamin E
One small trial (n=51) showed statistically significant reduction in hot flash severity and frequency compared to placebo 6, but this represents limited evidence from a single study.
Black Cohosh
Avoid due to hepatotoxicity concerns 5. Results are inconsistent and safety concerns preclude routine use.
Red Clover
No reduction in frequency demonstrated in meta-analysis 4. Not recommended.
Clinical Decision Framework
Choose venlafaxine or escitalopram if the patient has no contraindications and experiences hot flashes throughout the day.
Choose gabapentin if hot flashes are predominantly nocturnal or if the patient has contraindications to SSRIs/SNRIs.
Choose paroxetine mesylate if you prefer the only FDA-approved option, but ensure the patient is not taking tamoxifen.
Consider isoflavone supplementation only as an adjunct or if the patient strongly prefers supplements, but set realistic expectations about inconsistent evidence.
No head-to-head trials exist comparing these medications directly 2, so selection should be based on timing of symptoms (day vs night), comorbidities that might benefit from specific agents (e.g., depression favoring SSRIs), and patient preference.